Allogeneic haematopoietic cell transplantation for adult acute myeloid leukaemia in second remission: a retrospective study of the Adult Acute Myeloid Leukaemia Working Group of the Japan Society for Haematopoietic Cell Transplantation (JSHCT)

Takaaki Konuma; Masamitsu Yanada; Satoshi Yamasaki; Yachiyo Kuwatsuka; Takahiro Fukuda; Takeshi Kobayashi; Yukiyasu Ozawa; Naoyuki Uchida; Shuichi Ota; Takumi Hoshino; Satoshi Takahashi; Yoshinobu Kanda; Yasunori Ueda; Minoko Takanashi; Junya Kanda; Tatsuo Ichinohe; Yoshiko Atsuta; Shingo Yano

doi:10.1111/bjh.15399

Allogeneic haematopoietic cell transplantation for adult acute myeloid leukaemia in second remission: a retrospective study of the Adult Acute Myeloid Leukaemia Working Group of the Japan Society for Haematopoietic Cell Transplantation (JSHCT)

Br J Haematol. 2018 Jul;182(2):245-250. doi: 10.1111/bjh.15399. Epub 2018 May 29.

Authors

Takaaki Konuma¹, Masamitsu Yanada², Satoshi Yamasaki³, Yachiyo Kuwatsuka⁴, Takahiro Fukuda⁵, Takeshi Kobayashi⁶, Yukiyasu Ozawa⁷, Naoyuki Uchida⁸, Shuichi Ota⁹, Takumi Hoshino¹⁰, Satoshi Takahashi¹¹, Yoshinobu Kanda¹², Yasunori Ueda¹³, Minoko Takanashi¹⁴, Junya Kanda¹⁵, Tatsuo Ichinohe¹⁶, Yoshiko Atsuta^{17

18}, Shingo Yano¹⁹

Affiliations

¹ Department of Haematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
² Department of Haematology, Fujita Health University School of Medicine, Toyoake, Japan.
³ Department of Haematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Centre, Fukuoka, Japan.
⁴ Centre for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.
⁵ Department of Haematopoietic Stem Cell Transplantation, National Cancer Centre Hospital, Tokyo, Japan.
⁶ Haematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital, Tokyo, Japan.
⁷ Department of Haematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
⁸ Department of Haematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan.
⁹ Department of Haematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
¹⁰ Leukaemia Research Centre, Saiseikai Maebashi Hospital, Maebashi, Japan.
¹¹ Division of Molecular Therapy, The Advanced Clinical Research Centre, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
¹² Division of Haematology, Saitama Medical Centr, Jichi Medical University, Saitama, Japan.
¹³ Department of Haematology and Oncology, Kurashiki Central Hospital, Kurashiki, Japan.
¹⁴ Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
¹⁵ Department of Haematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
¹⁶ Department of Haematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
¹⁷ Japanese Data Centre for Haematopoietic Cell Transplantation, Nagoya, Japan.
¹⁸ Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan.
¹⁹ Division of Clinical Oncology and Haematology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.

PMID: 29808919
DOI: 10.1111/bjh.15399

Abstract

To evaluate the outcomes and prognostic factors following allogeneic haematopoietic cell transplantation (HCT) for adult acute myeloid leukaemia (AML) in second complete remission (CR2), we retrospectively analysed the Japanese registration data of 1080 adult AML patients in CR2 who had received allogeneic HCT. The probability of overall survival and the cumulative incidence of relapse at 3 years was 66% and 19%, respectively. In multivariate analysis, older age, poor cytogenetics and shorter duration of first complete remission were significantly associated with a higher overall mortality. Our data demonstrated the significant efficacy of allogeneic HCT for adult AML in CR2.

Keywords: acute myeloid leukaemia; allogeneic haematopoietic cell transplantation; duration of first complete remission; first relapse; second complete remission.

Publication types

Evaluation Study

MeSH terms

Adolescent
Adult
Aged
Disease-Free Survival
Female
Graft vs Host Disease / etiology
Hematopoietic Stem Cell Transplantation / methods*
Hematopoietic Stem Cell Transplantation / mortality
Humans
Leukemia, Myeloid, Acute / mortality
Leukemia, Myeloid, Acute / therapy*
Male
Middle Aged
Recurrence
Retrospective Studies
Transplantation, Homologous
Treatment Outcome
Young Adult